<?xml version='1.0' encoding='utf-8'?>
<document id="25394095"><sentence text="Efficacy, safety, and lack of interactions with the use of raltegravir in HIV-infected patients undergoing antineoplastic chemotherapy."><entity charOffset="59-70" id="DDI-PubMed.25394095.s1.e0" text="raltegravir" /></sentence><sentence text="Concomitant use of combination antiretroviral regimen (cART) and cancer chemotherapy is difficult due to complex interactions and increased toxicity" /><sentence text=" Raltegravir could be an adequate option through its favourable drug-drug interaction profile"><entity charOffset="1-12" id="DDI-PubMed.25394095.s3.e0" text="Raltegravir" /></sentence><sentence text="" /><sentence text="Prospective longitudinal study of HIV patients with cancer, AIDS related or not, undergoing chemotherapy" /><sentence text=" Patients without resistance or previous failure were switched or initiated raltegravir plus two nucleoside analogues"><entity charOffset="76-87" id="DDI-PubMed.25394095.s6.e0" text="raltegravir" /></sentence><sentence text=" Plasma trough levels of raltegravir were measured"><entity charOffset="25-36" id="DDI-PubMed.25394095.s7.e0" text="raltegravir" /></sentence><sentence text="" /><sentence text="Overall, 28 patients receiving a raltegravir-based regimen (4 naive) with tenofovir-emtricitabine (18 cases) or abacavir-lamivudine (10 cases) were included"><entity charOffset="33-44" id="DDI-PubMed.25394095.s9.e0" text="raltegravir" /><entity charOffset="74-83" id="DDI-PubMed.25394095.s9.e1" text="tenofovir" /><entity charOffset="112-120" id="DDI-PubMed.25394095.s9.e2" text="abacavir" /><entity charOffset="121-131" id="DDI-PubMed.25394095.s9.e3" text="lamivudine" /><pair ddi="false" e1="DDI-PubMed.25394095.s9.e0" e2="DDI-PubMed.25394095.s9.e0" /><pair ddi="false" e1="DDI-PubMed.25394095.s9.e0" e2="DDI-PubMed.25394095.s9.e1" /><pair ddi="false" e1="DDI-PubMed.25394095.s9.e0" e2="DDI-PubMed.25394095.s9.e2" /><pair ddi="false" e1="DDI-PubMed.25394095.s9.e0" e2="DDI-PubMed.25394095.s9.e3" /><pair ddi="false" e1="DDI-PubMed.25394095.s9.e1" e2="DDI-PubMed.25394095.s9.e1" /><pair ddi="false" e1="DDI-PubMed.25394095.s9.e1" e2="DDI-PubMed.25394095.s9.e2" /><pair ddi="false" e1="DDI-PubMed.25394095.s9.e1" e2="DDI-PubMed.25394095.s9.e3" /><pair ddi="false" e1="DDI-PubMed.25394095.s9.e2" e2="DDI-PubMed.25394095.s9.e2" /><pair ddi="false" e1="DDI-PubMed.25394095.s9.e2" e2="DDI-PubMed.25394095.s9.e3" /></sentence><sentence text=" Mean age was 46" /><sentence text="2 years (IQR, 39-52" /><sentence text="7), and 79% were male" /><sentence text=" Median time of HIV was 201" /><sentence text="7 months, CD4+ nadir was 268 cells/mm(3), and 75% had previous AIDS" /><sentence text=" At the diagnosis of neoplasia, 17 were on protease inhibitors and 4 with efavirenz"><entity charOffset="74-83" id="DDI-PubMed.25394095.s15.e0" text="efavirenz" /></sentence><sentence text=" Ten patients had a non-HIV-related cancer (three breast, two pancreatic, one Ewing sarcoma, one myeloblastic leukemia, one melanoma, one parotid adenocarcinoma, one lung), and 18 had an HIV-related cancer (nine non-Hodgkin lymphoma, seven Hodgkin disease, two anal)" /><sentence text=" Overall, 43% of patients received more than one line of chemotherapy, including antimetabolites in 12 patients (5-FU, capecitabine, methotrexate, gemcitabine), alkylating agents in 12 cases (ciclophosphamide, iphosphamide), vinca alkaloids in 20 patients (vincristine, vinblastine, vindesine), antitumor antibiotics in 16 cases (adriamycin), cisplatin o carboplatin in six and monoclonal antibodies in six patients (rituximab, trastuzumab, cetuximab)"><entity charOffset="113-117" id="DDI-PubMed.25394095.s17.e0" text="5-FU" /><entity charOffset="119-131" id="DDI-PubMed.25394095.s17.e1" text="capecitabine" /><entity charOffset="133-145" id="DDI-PubMed.25394095.s17.e2" text="methotrexate" /><entity charOffset="147-158" id="DDI-PubMed.25394095.s17.e3" text="gemcitabine" /><entity charOffset="192-208" id="DDI-PubMed.25394095.s17.e4" text="ciclophosphamide" /><entity charOffset="210-222" id="DDI-PubMed.25394095.s17.e5" text="iphosphamide" /><entity charOffset="231-240" id="DDI-PubMed.25394095.s17.e6" text="alkaloids" /><entity charOffset="257-268" id="DDI-PubMed.25394095.s17.e7" text="vincristine" /><entity charOffset="270-281" id="DDI-PubMed.25394095.s17.e8" text="vinblastine" /><entity charOffset="283-292" id="DDI-PubMed.25394095.s17.e9" text="vindesine" /><entity charOffset="330-340" id="DDI-PubMed.25394095.s17.e10" text="adriamycin" /><entity charOffset="343-352" id="DDI-PubMed.25394095.s17.e11" text="cisplatin" /><entity charOffset="355-366" id="DDI-PubMed.25394095.s17.e12" text="carboplatin" /><pair ddi="false" e1="DDI-PubMed.25394095.s17.e0" e2="DDI-PubMed.25394095.s17.e0" /><pair ddi="false" e1="DDI-PubMed.25394095.s17.e0" e2="DDI-PubMed.25394095.s17.e1" /><pair ddi="false" e1="DDI-PubMed.25394095.s17.e0" e2="DDI-PubMed.25394095.s17.e2" /><pair ddi="false" e1="DDI-PubMed.25394095.s17.e0" e2="DDI-PubMed.25394095.s17.e3" /><pair ddi="false" e1="DDI-PubMed.25394095.s17.e0" e2="DDI-PubMed.25394095.s17.e4" /><pair ddi="false" e1="DDI-PubMed.25394095.s17.e0" e2="DDI-PubMed.25394095.s17.e5" /><pair ddi="false" e1="DDI-PubMed.25394095.s17.e0" e2="DDI-PubMed.25394095.s17.e6" /><pair ddi="false" e1="DDI-PubMed.25394095.s17.e0" e2="DDI-PubMed.25394095.s17.e7" /><pair ddi="false" e1="DDI-PubMed.25394095.s17.e0" e2="DDI-PubMed.25394095.s17.e8" /><pair ddi="false" e1="DDI-PubMed.25394095.s17.e0" e2="DDI-PubMed.25394095.s17.e9" /><pair ddi="false" e1="DDI-PubMed.25394095.s17.e0" e2="DDI-PubMed.25394095.s17.e10" /><pair ddi="false" e1="DDI-PubMed.25394095.s17.e0" e2="DDI-PubMed.25394095.s17.e11" /><pair ddi="false" e1="DDI-PubMed.25394095.s17.e0" e2="DDI-PubMed.25394095.s17.e12" /><pair ddi="false" e1="DDI-PubMed.25394095.s17.e1" e2="DDI-PubMed.25394095.s17.e1" /><pair ddi="false" e1="DDI-PubMed.25394095.s17.e1" e2="DDI-PubMed.25394095.s17.e2" /><pair ddi="false" e1="DDI-PubMed.25394095.s17.e1" e2="DDI-PubMed.25394095.s17.e3" /><pair ddi="false" e1="DDI-PubMed.25394095.s17.e1" e2="DDI-PubMed.25394095.s17.e4" /><pair ddi="false" e1="DDI-PubMed.25394095.s17.e1" e2="DDI-PubMed.25394095.s17.e5" /><pair ddi="false" e1="DDI-PubMed.25394095.s17.e1" e2="DDI-PubMed.25394095.s17.e6" /><pair ddi="false" e1="DDI-PubMed.25394095.s17.e1" e2="DDI-PubMed.25394095.s17.e7" /><pair ddi="false" e1="DDI-PubMed.25394095.s17.e1" e2="DDI-PubMed.25394095.s17.e8" /><pair ddi="false" e1="DDI-PubMed.25394095.s17.e1" e2="DDI-PubMed.25394095.s17.e9" /><pair ddi="false" e1="DDI-PubMed.25394095.s17.e1" e2="DDI-PubMed.25394095.s17.e10" /><pair ddi="false" e1="DDI-PubMed.25394095.s17.e1" e2="DDI-PubMed.25394095.s17.e11" /><pair ddi="false" e1="DDI-PubMed.25394095.s17.e1" e2="DDI-PubMed.25394095.s17.e12" /><pair ddi="false" e1="DDI-PubMed.25394095.s17.e2" e2="DDI-PubMed.25394095.s17.e2" /><pair ddi="false" e1="DDI-PubMed.25394095.s17.e2" e2="DDI-PubMed.25394095.s17.e3" /><pair ddi="false" e1="DDI-PubMed.25394095.s17.e2" e2="DDI-PubMed.25394095.s17.e4" /><pair ddi="false" e1="DDI-PubMed.25394095.s17.e2" e2="DDI-PubMed.25394095.s17.e5" /><pair ddi="false" e1="DDI-PubMed.25394095.s17.e2" e2="DDI-PubMed.25394095.s17.e6" /><pair ddi="false" e1="DDI-PubMed.25394095.s17.e2" e2="DDI-PubMed.25394095.s17.e7" /><pair ddi="false" e1="DDI-PubMed.25394095.s17.e2" e2="DDI-PubMed.25394095.s17.e8" /><pair ddi="false" e1="DDI-PubMed.25394095.s17.e2" e2="DDI-PubMed.25394095.s17.e9" /><pair ddi="false" e1="DDI-PubMed.25394095.s17.e2" e2="DDI-PubMed.25394095.s17.e10" /><pair ddi="false" e1="DDI-PubMed.25394095.s17.e2" e2="DDI-PubMed.25394095.s17.e11" /><pair ddi="false" e1="DDI-PubMed.25394095.s17.e2" e2="DDI-PubMed.25394095.s17.e12" /><pair ddi="false" e1="DDI-PubMed.25394095.s17.e3" e2="DDI-PubMed.25394095.s17.e3" /><pair ddi="false" e1="DDI-PubMed.25394095.s17.e3" e2="DDI-PubMed.25394095.s17.e4" /><pair ddi="false" e1="DDI-PubMed.25394095.s17.e3" e2="DDI-PubMed.25394095.s17.e5" /><pair ddi="false" e1="DDI-PubMed.25394095.s17.e3" e2="DDI-PubMed.25394095.s17.e6" /><pair ddi="false" e1="DDI-PubMed.25394095.s17.e3" e2="DDI-PubMed.25394095.s17.e7" /><pair ddi="false" e1="DDI-PubMed.25394095.s17.e3" e2="DDI-PubMed.25394095.s17.e8" /><pair ddi="false" e1="DDI-PubMed.25394095.s17.e3" e2="DDI-PubMed.25394095.s17.e9" /><pair ddi="false" e1="DDI-PubMed.25394095.s17.e3" e2="DDI-PubMed.25394095.s17.e10" /><pair ddi="false" e1="DDI-PubMed.25394095.s17.e3" e2="DDI-PubMed.25394095.s17.e11" /><pair ddi="false" e1="DDI-PubMed.25394095.s17.e3" e2="DDI-PubMed.25394095.s17.e12" /><pair ddi="false" e1="DDI-PubMed.25394095.s17.e4" e2="DDI-PubMed.25394095.s17.e4" /><pair ddi="false" e1="DDI-PubMed.25394095.s17.e4" e2="DDI-PubMed.25394095.s17.e5" /><pair ddi="false" e1="DDI-PubMed.25394095.s17.e4" e2="DDI-PubMed.25394095.s17.e6" /><pair ddi="false" e1="DDI-PubMed.25394095.s17.e4" e2="DDI-PubMed.25394095.s17.e7" /><pair ddi="false" e1="DDI-PubMed.25394095.s17.e4" e2="DDI-PubMed.25394095.s17.e8" /><pair ddi="false" e1="DDI-PubMed.25394095.s17.e4" e2="DDI-PubMed.25394095.s17.e9" /><pair ddi="false" e1="DDI-PubMed.25394095.s17.e4" e2="DDI-PubMed.25394095.s17.e10" /><pair ddi="false" e1="DDI-PubMed.25394095.s17.e4" e2="DDI-PubMed.25394095.s17.e11" /><pair ddi="false" e1="DDI-PubMed.25394095.s17.e4" e2="DDI-PubMed.25394095.s17.e12" /><pair ddi="false" e1="DDI-PubMed.25394095.s17.e5" e2="DDI-PubMed.25394095.s17.e5" /><pair ddi="false" e1="DDI-PubMed.25394095.s17.e5" e2="DDI-PubMed.25394095.s17.e6" /><pair ddi="false" e1="DDI-PubMed.25394095.s17.e5" e2="DDI-PubMed.25394095.s17.e7" /><pair ddi="false" e1="DDI-PubMed.25394095.s17.e5" e2="DDI-PubMed.25394095.s17.e8" /><pair ddi="false" e1="DDI-PubMed.25394095.s17.e5" e2="DDI-PubMed.25394095.s17.e9" /><pair ddi="false" e1="DDI-PubMed.25394095.s17.e5" e2="DDI-PubMed.25394095.s17.e10" /><pair ddi="false" e1="DDI-PubMed.25394095.s17.e5" e2="DDI-PubMed.25394095.s17.e11" /><pair ddi="false" e1="DDI-PubMed.25394095.s17.e5" e2="DDI-PubMed.25394095.s17.e12" /><pair ddi="false" e1="DDI-PubMed.25394095.s17.e6" e2="DDI-PubMed.25394095.s17.e6" /><pair ddi="false" e1="DDI-PubMed.25394095.s17.e6" e2="DDI-PubMed.25394095.s17.e7" /><pair ddi="false" e1="DDI-PubMed.25394095.s17.e6" e2="DDI-PubMed.25394095.s17.e8" /><pair ddi="false" e1="DDI-PubMed.25394095.s17.e6" e2="DDI-PubMed.25394095.s17.e9" /><pair ddi="false" e1="DDI-PubMed.25394095.s17.e6" e2="DDI-PubMed.25394095.s17.e10" /><pair ddi="false" e1="DDI-PubMed.25394095.s17.e6" e2="DDI-PubMed.25394095.s17.e11" /><pair ddi="false" e1="DDI-PubMed.25394095.s17.e6" e2="DDI-PubMed.25394095.s17.e12" /><pair ddi="false" e1="DDI-PubMed.25394095.s17.e7" e2="DDI-PubMed.25394095.s17.e7" /><pair ddi="false" e1="DDI-PubMed.25394095.s17.e7" e2="DDI-PubMed.25394095.s17.e8" /><pair ddi="false" e1="DDI-PubMed.25394095.s17.e7" e2="DDI-PubMed.25394095.s17.e9" /><pair ddi="false" e1="DDI-PubMed.25394095.s17.e7" e2="DDI-PubMed.25394095.s17.e10" /><pair ddi="false" e1="DDI-PubMed.25394095.s17.e7" e2="DDI-PubMed.25394095.s17.e11" /><pair ddi="false" e1="DDI-PubMed.25394095.s17.e7" e2="DDI-PubMed.25394095.s17.e12" /><pair ddi="false" e1="DDI-PubMed.25394095.s17.e8" e2="DDI-PubMed.25394095.s17.e8" /><pair ddi="false" e1="DDI-PubMed.25394095.s17.e8" e2="DDI-PubMed.25394095.s17.e9" /><pair ddi="false" e1="DDI-PubMed.25394095.s17.e8" e2="DDI-PubMed.25394095.s17.e10" /><pair ddi="false" e1="DDI-PubMed.25394095.s17.e8" e2="DDI-PubMed.25394095.s17.e11" /><pair ddi="false" e1="DDI-PubMed.25394095.s17.e8" e2="DDI-PubMed.25394095.s17.e12" /><pair ddi="false" e1="DDI-PubMed.25394095.s17.e9" e2="DDI-PubMed.25394095.s17.e9" /><pair ddi="false" e1="DDI-PubMed.25394095.s17.e9" e2="DDI-PubMed.25394095.s17.e10" /><pair ddi="false" e1="DDI-PubMed.25394095.s17.e9" e2="DDI-PubMed.25394095.s17.e11" /><pair ddi="false" e1="DDI-PubMed.25394095.s17.e9" e2="DDI-PubMed.25394095.s17.e12" /><pair ddi="false" e1="DDI-PubMed.25394095.s17.e10" e2="DDI-PubMed.25394095.s17.e10" /><pair ddi="false" e1="DDI-PubMed.25394095.s17.e10" e2="DDI-PubMed.25394095.s17.e11" /><pair ddi="false" e1="DDI-PubMed.25394095.s17.e10" e2="DDI-PubMed.25394095.s17.e12" /><pair ddi="false" e1="DDI-PubMed.25394095.s17.e11" e2="DDI-PubMed.25394095.s17.e11" /><pair ddi="false" e1="DDI-PubMed.25394095.s17.e11" e2="DDI-PubMed.25394095.s17.e12" /></sentence><sentence text=" Six patients modified the doses of antineoplastic agents due to toxicity (four neutropenia), not related to raltegravir"><entity charOffset="109-120" id="DDI-PubMed.25394095.s18.e0" text="raltegravir" /></sentence><sentence text=" During a median follow up of 12" /><sentence text="7 patients-year in concomitant therapy, there was only 1 case of virological failure and no patient discontinued raltegravir"><entity charOffset="113-124" id="DDI-PubMed.25394095.s20.e0" text="raltegravir" /></sentence><sentence text=" Plasma concentrations of raltegravir in eight patients showed a median concentration of 143 ng/mL (79-455)"><entity charOffset="26-37" id="DDI-PubMed.25394095.s21.e0" text="raltegravir" /></sentence><sentence text=" Four patients (14%) died during the study, not related to AIDS progression" /><sentence text=" Raltegravir was continued after chemotherapy in all the cases"><entity charOffset="1-12" id="DDI-PubMed.25394095.s23.e0" text="Raltegravir" /></sentence><sentence text="" /><sentence text="A raltegravir-based therapy is safe and effective in HIV patients undergoing antineoplastic chemotherapy, regardless of the type of tumour, and type and duration of chemotherapy" /><sentence text=" Pharmacokinetic data show adequate raltegravir levels"><entity charOffset="36-47" id="DDI-PubMed.25394095.s26.e0" text="raltegravir" /></sentence><sentence text="" /></document>